Market Closed -
Nasdaq
01:30:00 18/05/2024 am IST
5-day change
1st Jan Change
24.24
USD
+0.08%
0.00%
+12.33%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to Castle Bioscien...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing
09/05
MT
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival in Patients Diagnosed with UM
09/05
CI
Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024
03/05
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M
03/05
MT
Castle Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
03/05
CI
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024
03/05
CI
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
09/04
MT
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress
05/04
CI
Castle Biosciences, Inc. Announces Board Changes
28/03
CI
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology
19/03
CI
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test
07/03
CI
Transcript : Castle Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024
29/02
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q4 Revenue $66.1M, vs. Street Est of $61.2M
29/02
MT
Castle Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
29/02
CI
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024
29/02
CI
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
29/02
CI
Castle Biosciences Insider Sold Shares Worth $493,818, According to a Recent SEC Filing
08/02
MT
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii
14/01
CI
Castle Biosciences Insider Sold Shares Worth $475,585, According to a Recent SEC Filing
09/01
MT
Castle Biosciences Sees 53% Growth in Annual Revenue in 2023
08/01
MT
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023
08/01
CI
Castle Biosciences Insider Sold Shares Worth $301,774, According to a Recent SEC Filing
30/12
MT
Castle Biosciences Insider Sold Shares Worth $260,466, According to a Recent SEC Filing
28/12
MT
Castle Biosciences Insider Sold Shares Worth $393,446, According to a Recent SEC Filing
23/12
MT
Castle Biosciences Insider Sold Shares Worth $334,542, According to a Recent SEC Filing
21/12
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
More about the company
Last Close Price
24.22
USD
Average target price
34.33
USD
Spread / Average Target
+41.76%
Consensus
1st Jan change
Capi.
+12.33% 67Cr -4.67% 1.23TCr -5.19% 814.08Cr +28.50% 562.13Cr -8.09% 424.41Cr -55.31% 306.33Cr +13.49% 275.67Cr -1.34% 240.89Cr +32.24% 222.74Cr -3.55% 186.6Cr
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1